Management of Mild Hepatocellular Injury

Severity Classification and Pattern Recognition

The American Association for the Study of Liver Diseases recommends that mild hepatocellular injury, defined as <5× the upper limit of normal (ULN), be systematically evaluated to identify the underlying cause, with nonalcoholic fatty liver disease (NAFLD) being the most likely diagnosis given the AST:ALT ratio of approximately 0.85 1, 2
The AST:ALT ratio of 0.85 (<1) strongly suggests NAFLD, viral hepatitis, or medication-induced liver injury rather than alcoholic liver disease, which typically shows an AST:ALT ratio >2, according to the Mayo Clinic Proceedings 3, 2
This hepatocellular pattern (elevated transaminases with normal alkaline phosphatase) indicates liver cell damage rather than biliary obstruction, as stated in the Journal of Hepatology 4

The American College of Gastroenterology recommends completing the following tests within 2-4 weeks: complete liver panel, viral hepatitis serologies, metabolic parameters, and creatine kinase (CK) to exclude muscle injury as the source of AST elevation 1, 2
The complete liver panel should include alkaline phosphatase, total and direct bilirubin, albumin, prothrombin time/INR to assess synthetic function and rule out cholestatic patterns, as suggested by Praxis Medical Insights 1, 2
Viral hepatitis serologies, including HBsAg, anti-HBc IgM, and HCV antibody, should be performed to exclude viral hepatitis as a cause, according to Praxis Medical Insights 1, 2
Metabolic parameters, such as fasting glucose or HbA1c, fasting lipid panel, and assessment for metabolic syndrome components, including waist circumference and blood pressure, should be evaluated, as recommended by the Mayo Clinic Proceedings 3, 1

The FIB-4 score, calculated using age, ALT, AST, and platelet count, helps determine the risk of advanced fibrosis, with a score >2.67 indicating high risk, according to the Mayo Clinic Proceedings 3, 1, 2
A FIB-4 score >2.67 requires hepatology referral, as stated in the Mayo Clinic Proceedings 3

If NAFLD is confirmed, lifestyle modifications, including weight loss, exercise, and dietary changes, are the cornerstone of treatment, as recommended by Praxis Medical Insights 1, 2
The American Association for the Study of Liver Diseases suggests that weight loss target should be 7-10% body weight reduction through caloric restriction, and exercise prescription should be 150-300 minutes of moderate-intensity aerobic exercise weekly 1
Dietary changes, such as a low-carbohydrate, low-fructose diet, should be implemented, as suggested by Praxis Medical Insights 1
Metabolic comorbidities, such as diabetes and dyslipidemia, should be managed aggressively, according to Praxis Medical Insights 1

The American College of Gastroenterology recommends repeating liver enzymes in 2-4 weeks to establish the trend and direction of change, and continuing monitoring every 4-8 weeks until stabilized 1
If ALT increases to >3× baseline or >300 U/L, urgent evaluation within 2-3 days for alternative etiologies is necessary, as stated by Praxis Medical Insights 1
If ALT increases to >5× ULN (>235 U/L for males, >125 U/L for females), immediate hepatology referral is required, according to Praxis Medical Insights 1, 2

The American Association for the Study of Liver Diseases recommends referring to hepatology immediately if ALT increases to >5× ULN (>235 U/L for males, >125 U/L for females), total bilirubin increases to >2× ULN, or evidence of synthetic dysfunction (elevated INR, low albumin, thrombocytopenia) 1, 2, 3
A FIB-4 score >2.67 indicating high risk for advanced fibrosis also requires urgent specialist referral, as stated in the Mayo Clinic Proceedings 3

The American College of Gastroenterology warns against assuming NAFLD without proper evaluation, as ALT elevation ≥5× ULN is rare in NAFLD alone and requires investigation for viral hepatitis, autoimmune hepatitis, or drug-induced liver injury 1
Non-hepatic causes, such as intensive exercise or muscle injury from manual labor, can elevate transaminases, particularly AST, and should not be overlooked, as stated by Praxis Medical Insights 1, 2
Normal ALT does not rule out NAFLD or advanced fibrosis, and up to 50% of NAFLD patients have normal liver enzymes, according to the Mayo Clinic Proceedings 3, 1